2021 Keynotes

TUESDAY, 5 OCTOBER

DIGITAL TRANSFORMATION AND EXPANDING ON INNOVATION LESSONS FROM COVID-19

11:45 Chairperson's Remarks
Nick Carroll, PhDNick Carroll, PhD, Transformation Lead, Digital Health, R&D, AstraZeneca



11:50 FIRESIDE CHAT: Combining Innovation and Collaboration to Advance Research Across the Industry...We Can’t Do it Alone
Sam HarirySam Hariry, Global Head, Clinical Innovation, Novartis Institutes for BioMedical Research (NIBR)
Lewis MillenLewis Millen, Operations Innovation Lead, Global Clinical Sciences & Dev Solutions, UCB Pharma
The biopharma, medical device, digital medicine, healthcare and tech industries involved in clinical research are learning from one another, improving innovation, re-thinking business process, and expanding what used to be a much more siloed ecosystem. These are exciting times, but it is a very complex garden to navigate. How do we continue to innovate beyond pilots? How do we scale innovation and collaborate across departments, companies and industries to improve clinical trials and research?


12:20 Digital Transformation of an Entire Biopharma Company Look Like?
Francesca Wuttke, PhDFrancesca Wuttke, PhD, Chief Digital Officer, Almirall
Biopharma companies are trying to change business processes, drug discovery, manufacturing, clinical trials…their entire cultures, to provide more digital solutions and services to their customers but it’s a long road. What are the main impediments to adoption? How can companies do different things (digitally enabled business models) rather than just do things differently (digitization)? Where can companies find the best chance of success and how do they start? How can large pharma, biotech, specialty pharma and traditional life sci organizations transition?


12:30 Digital Health in the Circular Economy, Novel Partnerships Required
Bert Hartog, PhDBert Hartog, PhD, Senior Director Clinical Innovation, Janssen Pharmaceutica NV
The talk will be about the environmental impact of digital health, and how circular economy principles can help minimize eWaste and maximize repurposing, reuse and recycling of digital health technologies.



12:40 PANEL DISCUSSION: What Can Clinical Innovation Teams Learn from Digital Health Startups?

PANEL MODERATOR:
Francesca Wuttke, PhDFrancesca Wuttke, PhD, Chief Digital Officer, Almirall SA
Working with startups can provide the Pharma industry with the innovation capabilities required to accelerate the digital transformation of the company, while embedding a culture of experimentation where there is freedom to try and fail, through the exposure to and collaboration with young and risk-taking startups. Partnering with Startups offers Pharma access to solution-driven technology which allows them to accelerate their growth and drive strategy.


PANELISTS:
Andrea CoravosAndrea Coravos, CEO & Co-Founder, Elektra Labs
Bert Hartog, PhDBert Hartog, PhD, Senior Director Clinical Innovation, Janssen Pharmaceutica NV
Nader AlaghbandNader Alaghband, Co-Founder & CEO, Ampersand Health


WEDNESDAY, 6 OCTOBER

SPECIAL CATALAN ECOSYSTEM PANEL: DIGITAL TRANSFORMATION AND CLINICAL TRIALS

10:35 PANEL DISCUSSION: Special Catalan Ecosystem Panel: Digital Transformation and Clinical trials: The Next Challenge in Health

PANEL MODERATOR:
Montse DabanMontse Daban, Directcor, Scientific and International Relations, Biocat
The healthcare community agrees on the need to foster digital transformation throughout the entire healthcare value chain, including the framework for the clinical validation of innovative technologies, i.e., the evidence for real-world positive and significant health outcomes for patients and society. The final objective is to accelerate technology adoption, provide support for the validated ideas, and improve their market access. The session will share perspectives of actors connecting clinical research and industry in a comprehensive way and it will highlight the successful coordination in clinical trials key stakeholders in Catalonia.

PANELISTS:
Montserrat Barcelo RieraMontserrat Barcelo Riera, Vice President, Europe, Veristat
Xavier CañasXavier Cañas, Director, Promotion and Development of Clinical Research, Vall d’Hebron Hospital
Dani Prieto-AlhambraDani Prieto-Alhambra, MD, PhD, Professor, Pharmaco- and Device Epidemiology, University of Oxford
Lidia Cánovas, General Manager, Regulatory Affairs, AsphalionDani Prieto-Alhambra



11:05 Exhibit Hall Viewing

ROLE OF HEALTH DATA EXCHANGE & IMPLEMENTING HYBRID/DECENTRALIZED TRIALS

11:50 Chairperson's Remarks
Karl-Ludwig RadekKarl-Ludwig Radek, Internal Project Lead for IMI Trials@Home, Janssen



11:55 Harnessing the Power of Rea-World Data for Clinical Research: European Initiatives
Dipak Kalra, PhDDipak Kalra, PhD, President, European Institute for Health Records and European Institute for Innovation through Health Data
Real World Data has historically been regarded as siloed within healthcare provider systems (and therefore fragmented, difficult to access at scale), with patchy coverage and often of poor quality - so not very reliable for research. A further barrier is data protection legislation, in Europe with the GDPR. Large-scale research infrastructure initiatives are now being established across Europe to tackle these issues and to make RWD more available for observational data studies and the reuse of EHRs for clinical trials. This talk will present this exciting landscape, including the Commission proposals for a European Health Data Space, and explain how some of the perceived issues with RWD are being tackled, including winning public support for the use of RWD by industry.


12:15 PANEL DISCUSSION: Hybrid and Decentralized Trials: The Future is Here
PANEL MODERATOR:
Karl-Ludwig RadekKarl-Ludwig Radek, Internal Project Lead for IMI Trials@Home, Janssen
Covid-19 has played an extreme catalyst role in implementing existing digital and remote clinical trial solutions and has been the engine behind rapid evolution of a few new capabilities. Some of these newly deployed capabilities are quick fixes for the emergency that COVID brought to our day-to-day trial operations, while many will benefit from the catalyst effect and will probably be the new standard even after COVID. Today, we have the chance to continue driving adoption of decentralized clinical trials – and innovating to advance the benefits DCTs offer to patients, sites and sponsors.


PANELISTS:
Dipak Kalra, PhDDipak Kalra, PhD, President, European Institute for Health Records & President, European Institute for Innovation through Health Data
Cristina De Juan, PhDCristina De Juan, PhD, Innovation Lead, Global Clinical Sciences and Operations (GCSO), UCB
Joseph KimJoseph Kim, Head of Healthcare and Visual Analytics, Data Science & AI, AstraZeneca Biopharmaceuticals R&D
Marta Arias-Salgado Ruiz-GimenezMarta Arias-Salgado Ruiz-Gimenez, Head of Quality & Continuous Improvement, Global Clinical Trials Organization, MSD
Kavita Rattan, PhDKavita Rattan, PhD, Lead, AI-Data Sciences & RBM, Data Monitoring & Management, Pfizer Inc.